Periodic Reporting for period 2 - CD20CARNAPT (iTANK: a nuniversal technology to boost the efficacy of CAR T cell therapies by inducing dual mode-of-actio)

Chimeric antigen receptor CAR-T cell therapy has been approved as a second/third-line treatment for patients with chemotherapy-resistant B cell tumors. So far, four therapies with CD19 CAR-T cells have been approved in the EU for B-cell leukemia and lymphoma (Yescarta...